AVR vs EW vs MDT vs NVCR

For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.

5% revenue growth year-over-year, versus -1. 2% for Anteris Technologies Global Corp. (AVR). Medtronic plc (MDT) offers the better valuation at 21. 1x trailing P/E (13. 8x forward), making it the more compelling value choice. Analysts rate Anteris Technologies Global Corp. (AVR) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

1x versus Edwards Lifesciences Corporation at 43. 7x. On forward P/E, Medtronic plc is actually cheaper at 13. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Edwards Lifesciences Corporation wins at 3. 75x versus Medtronic plc's 35. 17x.

Over the past 5 years, Anteris Technologies Global Corp.

(AVR) delivered a total return of +17. 5%, compared to -90. 2% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: EW returned +125. 5% versus AVR's +17. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

42β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 406% more volatile than MDT relative to the S&P 500. On balance sheet safety, Anteris Technologies Global Corp. (AVR) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.

5% versus -1. 2% for Anteris Technologies Global Corp. (AVR). On earnings-per-share growth, the picture is similar: Medtronic plc grew EPS 30. 8% year-over-year, compared to -194. 5% for Anteris Technologies Global Corp.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus -28. 2% for Anteris Technologies Global Corp. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -29. 0% for AVR. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Edwards Lifesciences Corporation (EW) is the more undervalued stock at a PEG of 3. 75x versus Medtronic plc's 35. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 13. 8x forward P/E versus 26. 6x for Edwards Lifesciences Corporation — 12. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AVR: 128. 0% to $15. 00.

In this comparison, MDT (3.

7% yield) pays a dividend. AVR, EW, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

42), 3. 7% yield). Anteris Technologies Global Corp. (AVR) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +24. 3%, AVR: +17. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AVR is a small-cap quality compounder stock; EW is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock; NVCR is a small-cap quality compounder stock. MDT pays a dividend while AVR, EW, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.